CompletedPhase 3

Lipid Efficacy Study (0524B-022)(COMPLETED)

1,400 participantsStarted 2006-01

Plain-language summary

This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients 18 to 85 years of age with primary hypercholesterolemia or mixed hyperlipidemia * LDL-C between 130 and 190 mg/L (Category I) and 130 and 160 mg/L (Category II) and triglycerides \</= 350 mg/dL. Exclusion Criteria: * A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study * Patients with \<80% compliance * Patients with certain medical conditions * Patients taking certain concomitant medications and/or with unstable doses of medications * Or those with a history of CHD/CHD equivalent or diabetes

What they're measuring

Coadministered MK0524B will be more efficacious in reducing LDL-C concentrations compared to MK0524A.

Trial details

NCT IDNCT00269217

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-01

View on ClinicalTrials.gov More Primary Hypercholesterolemia trials